- RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
This study is looking into a new treatment called KarXT + KarX-EC for people with mild to moderate Alzheimer's disease. Researchers want to see if it can help improve memory and thinking, and if it's safe to use.
For: Alzheimer's DiseaseUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
This study looks at a new medicine for agitation in people with Alzheimer's. It aims to see if an experimental drug, given as capsules, is safe and works well over a long time for those who've been in similar studies before.
For: Alzheimer Disease · AgitationUnited States · Argentina · Brazil - AuthorisedTherapeutic confirmatory (Phase III)
CN012-0025: A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-3)
This study looks at a new drug, KarXT, for people with Alzheimer's disease who experience agitation. It's an extension of previous studies, checking the long-term safety and how well people tolerate the medication. Researchers want to see if it causes any unwanted side effects over time.
For: Agitation Associated with Alzheimer’s DiseaseCroatia · Romania · France - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 years of age) with Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 years of age) with Irritability Associated with Autism Spectrum Disorder
This study looks at new medicines (KarXT and KarX-EC) for young people aged 5-17. It checks how safe they are and if they cause any side effects for teenagers with schizophrenia or children/teenagers with autism who have a lot of irritability.
For: Schizophrenia and Autism Spectrum Disorder (ASD)Romania - RecruitingPHASE3
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
This study is looking at a new treatment called KarXT + KarX-EC for psychosis, which can affect people with Alzheimer's disease. Researchers want to see if this treatment is safe and helps reduce psychotic symptoms like hallucinations or delusions in individuals aged 55 to 90.
For: Alzheimer Disease · PsychosisUnited States · Australia · Canada